These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 38727085)
21. Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment. Lai CC; Hsueh PR J Med Virol; 2023 Feb; 95(2):e28430. PubMed ID: 36571273 [TBL] [Abstract][Full Text] [Related]
22. Budget impact of oral nirmatrelvir/ritonavir in adults at high risk for progression to severe COVID-19 in the United States. Sandin R; Veenstra DL; Vankelegom M; Dzingina M; Sullivan SD; Campbell D; Ma C; Harrison C; Draica F; Wiemken TL; Mugwagwa T J Manag Care Spec Pharm; 2023 Dec; 29(12):1290-1302. PubMed ID: 38058141 [TBL] [Abstract][Full Text] [Related]
23. The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants. Hsu CK; Hsu WH; Shiau BW; Tsai YW; Wu JY; Liu TH; Huang PY; Chuang MH; Lai CC Expert Rev Anti Infect Ther; 2024 Apr; ():1-8. PubMed ID: 38568820 [TBL] [Abstract][Full Text] [Related]
24. Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12-17 years following SARS-CoV-2 Omicron infection: A target trial emulation. Wong CKH; Lau KTK; Au ICH; Chan SHS; Lau EHY; Cowling BJ; Leung GM Nat Commun; 2024 Jun; 15(1):4917. PubMed ID: 38851796 [TBL] [Abstract][Full Text] [Related]
25. Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial. Geng LN; Bonilla H; Hedlin H; Jacobson KB; Tian L; Jagannathan P; Yang PC; Subramanian AK; Liang JW; Shen S; Deng Y; Shaw BJ; Botzheim B; Desai M; Pathak D; Jazayeri Y; Thai D; O'Donnell A; Mohaptra S; Leang Z; Reynolds GZM; Brooks EF; Bhatt AS; Shafer RW; Miglis MG; Quach T; Tiwari A; Banerjee A; Lopez RN; De Jesus M; Charnas LR; Utz PJ; Singh U JAMA Intern Med; 2024 Sep; 184(9):1024-1034. PubMed ID: 38848477 [TBL] [Abstract][Full Text] [Related]
26. Clinical effectiveness of oral antiviral agents for treating non-hospitalized COVID-19 patients with chronic kidney disease. Chen CC; Huang CY; Wu JY; Liu MY; Chuang MH; Liu TH; Tsai YW; Hsu WH; Huang PY; Chen MH; Liu SY; Lee MC; Hung KC; Lai CC; Yang IN Expert Rev Anti Infect Ther; 2024 Mar; ():1-8. PubMed ID: 38525673 [TBL] [Abstract][Full Text] [Related]
27. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes. Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Mutalik P; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN Ann Intern Med; 2023 Jun; 176(6):807-816. PubMed ID: 37276589 [TBL] [Abstract][Full Text] [Related]
28. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM; N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054 [TBL] [Abstract][Full Text] [Related]
29. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study. Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795 [TBL] [Abstract][Full Text] [Related]
30. Real-World Study on Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting. Kwok WC; Tsoi MF; Leung SHI; Tsui CK; Tam TCC; Ho JCM; Lam DCL; Ip MSM; Ho PL Viruses; 2023 Feb; 15(3):. PubMed ID: 36992319 [TBL] [Abstract][Full Text] [Related]
31. The effect of oral antiviral therapy for COVID-19 in managing non-hospitalized patients with lung cancer. Hsu WH; Shiau BW; Tsai YW; Wu JY; Huang PY; Chuang MH; Liu TH; Lai CC; Weng TC J Infect Public Health; 2024 Aug; 17(8):102465. PubMed ID: 38878678 [TBL] [Abstract][Full Text] [Related]
32. Nirmatrelvir/Ritonavir Use and Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-Risk Population With COVID-19: A Matched Cohort Study. Butt AA; Yan P; Shaikh OS; Talisa VB; Omer SB; Mayr FB J Infect Dis; 2024 Jan; 229(1):147-154. PubMed ID: 37711076 [TBL] [Abstract][Full Text] [Related]
34. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912 [TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States. Carlson J; Foos V; Kasle A; Mugwagwa T; Draica F; Lee Wiemken T; Nguyen JL; Cha-Silva A; Migliaccio-Walle K; Dzingina M Value Health; 2024 Feb; 27(2):164-172. PubMed ID: 38043712 [TBL] [Abstract][Full Text] [Related]
37. Oral COVID-19 Antiviral Uptake Among a Highly Vaccinated US Cohort of Adults With SARS-CoV-2 Infection Between December 2021 and October 2022. Shen Y; Robertson MM; Kulkarni SG; Puzniak L; Zamparo JM; Allen KE; Porter TM; Qasmieh SA; Grov C; Srivastava A; Zimba R; McLaughlin JM; Nash D Open Forum Infect Dis; 2024 Feb; 11(2):ofad674. PubMed ID: 38344131 [TBL] [Abstract][Full Text] [Related]
38. Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting. Mutoh Y; Umemura T; Nishikawa T; Kondo K; Nishina Y; Soejima K; Noguchi Y; Bando T; Ota S; Shimahara T; Hirota S; Hagimoto S; Takei R; Fukihara J; Sasano H; Yamano Y; Yokoyama T; Kataoka K; Matsuda T; Kimura T; Ichihara T; Kondoh Y Viruses; 2023 Mar; 15(3):. PubMed ID: 36992519 [TBL] [Abstract][Full Text] [Related]